Abstract
Recent studies have identified new melanoma antigens that are recognised by CD4(+) T cells. Analysis of tumour-specific CD4(+) T-cell responses may lead to the development of optimal anti-cancer vaccines that can induce an orchestrated effort of tumour-specific CD4(+) and CD8(+) T cells in the fight against cancer.
MeSH terms
-
Animals
-
Antigen Presentation
-
Antigens, Neoplasm / immunology
-
CD4-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / immunology*
-
Cancer Vaccines / immunology
-
Histocompatibility Antigens Class II / immunology
-
Immunologic Surveillance
-
Melanoma / immunology
-
Mice
-
Models, Immunological
-
Neoplasms / immunology*
-
Neoplasms / prevention & control
-
Neoplasms / therapy
-
Neoplasms, Experimental / immunology
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines
-
Histocompatibility Antigens Class II